BioCentury | Nov 30, 2020
Finance

Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...
BioCentury | Nov 20, 2020
Regulation

WHO counters FDA as it recommends against Veklury for COVID-19

...or ECMO.The EUA is based on data from NIH’s ACTT-2 trial, which showed the oral JAK-1/JAK-2...
...Compound #), INCB28050 (Former compound #), baricitinib (Generic), Olumiant (Other) Gilead Sciences Inc. Eli Lilly and Co. Incyte Corp. Janus kinase-1 (JAK-1) Janus...
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

Metagenomi is systematizing the search for new gene editing tools by scouring the genomes of bacteria in ecological samples. The company emerged from stealth Thursday with a $65 million series A round...
BioCentury | Nov 11, 2020
Product Development

Arena sees clear path to atopic dermatitis Phase III for etrasimod despite data that shed $1B in value

...show a greater benefit to compete with JAK-1...
...may have an advantage is on safety. JAK-1...
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

EMA reviewing filgotinib for ulcerative colitisGilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said EMA is reviewing its MAA for Jyseleca filgotinib to treat ulcerative colitis. The partners are seeking the JAK inhibitor’s approval...
BioCentury | Oct 29, 2020
Product Development

Gilead leaning on cancer deals for growth as filgotinib’s future hangs in the balance

As it awaits more clarity on a path forward for autoimmune candidate filgotinib, Gilead is leaning on its recent spate of cancer deals, most notably with ADC developer Immunomedics, for near-term growth.  Filgotinib, the centerpiece of...
BioCentury | Oct 22, 2020
Product Development

Data Byte: AbbVie’s oral JAK takes the lead in coming competition for Dupixent in atopic dermatitis

...efficacy, compared with three other Phase III programs and the marketed therapy Dupixent dupilumab.The oral JAK-1...
...Dermatology (EADV) Virtual Congress from Oct. 29-31.All endpoint data are at 16 weeks except for JAK-1...
...3 and CHRONOS trials tested the therapies in combination with topical steroids.Olumiant baracitinib is a JAK-1...
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...
BioCentury | Oct 13, 2020
Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients

...significance vs. placebo.Jyseleca is more selective for JAK-1...
...against the same targets aren’t far behind. JAK-1...
...1 Stephen Hansen Jyseleca, filgotinib (GLPG0634, GS-6034) Gilead Sciences Inc. Galapagos N.V. Janus kinase-1 (JAK-1) Sphingosine...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

FDA moving quickly on Biogen’s aducanumab Biogen Inc. (NASDAQ:BIIB) added $1.4 billion in market cap Monday, as its shares rose $8.73 (3.2%) to $282.04, after FDA said it will hold an advisory...
Items per page:
1 - 10 of 868